Ring Nitrogen In The Pentacyclo Ring System Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.) Patents (Class 514/283)
-
Publication number: 20110071179Abstract: The present invention relates to the use of novel macrocyclic compounds of Formula I, wherein the variables Q, Q1, Q2, Q3, and Q4 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.Type: ApplicationFiled: September 17, 2010Publication date: March 24, 2011Inventors: Alam Jahangir, Stephen M. Lynch, Michael Soth, Hanbiao Yang
-
Patent number: 7910593Abstract: An objective of the present invention is to provide water-soluble prodrugs that can be administered parenterally, and which show excellent water solubility and small interspecies or individual differences and are rapidly converted to the active form by chemical conversion. This invention provides water-soluble prodrugs represented by formula (1), or pharmaceutically acceptable salts, or hydrates or solvates thereof, (wherein, R1 represents a hydrogen atom, or C1-C6 alkyl group; W represents a divalent group comprising a tertiary amino group or sulfonyl group; and Y represents a residue of a compound represented by Y—OH comprising an alcoholic hydroxyl group).Type: GrantFiled: April 8, 2005Date of Patent: March 22, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Isao Umeda, Jun Ohwada, Sawako Ozawa
-
Publication number: 20110059076Abstract: Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.Type: ApplicationFiled: April 9, 2010Publication date: March 10, 2011Inventors: Charlotte McDonagh, Michael Feldhaus, Alexandra Huhalov
-
Publication number: 20110059183Abstract: A method of producing water-insoluble anti-cancer drug in the form of particulates, the method including preparing a water-insoluble anti-cancer drug having at least one multiple bond in the structure, and irradiating said water-insoluble anti-cancer drug with a laser beam having a wavelength of a low absorption portion in the vicinity of the foot of an absorption curve on the long wavelength side within the absorption band until said water-insoluble anti-cancer drug is formed into particulates having an average particle diameter of 50 to 200 nm.Type: ApplicationFiled: September 10, 2010Publication date: March 10, 2011Applicant: EBARA CORPORATIONInventors: Hiroyuki KATO, Isao Umeda, Kazuo Watanabe, Kazuya Hirata, Akio Ishiguro, Tetsu Go
-
Publication number: 20110059977Abstract: The present invention relates to the use, for the preparation of a medicament intended for the treatment or the prevention of pathologies linked to, or caused by mycobacteria, of at least one of the compounds of the following formula (I): in which B represents in particular a nitrogen atom, and R1, R2, R3, R4, R5, R6, R7 and R8 represent in particular a hydrogen atom.Type: ApplicationFiled: March 22, 2007Publication date: March 10, 2011Applicant: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (I.R.D.)Inventors: Alain Robert Francois Maxime Fournet, Delphine Lagoutte, Erwan Poupon, Flor Soriano-Agaton
-
Publication number: 20110053972Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: ApplicationFiled: February 7, 2008Publication date: March 3, 2011Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Mark Andrew Seefeld, Meagan B. Rouse
-
Publication number: 20110044940Abstract: The present invention relates to novel Heterocyclic Ether or Thioether Derivatives, compositions comprising the Heterocyclic Ether or Thioether Derivatives, and methods for using the Heterocyclic Ether or Thioether Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase.Type: ApplicationFiled: October 27, 2008Publication date: February 24, 2011Inventors: Gerald W. Shipps, JR., Matthew Richards, Cliff C. Cheng, Xiaohua Huang
-
Publication number: 20110045092Abstract: Casein particles, such as micelles or clusters thereof, having encapsulated therein hydrophobic and/or water insoluble therapeutically active agents such as hydrophobic chemotherapeutic agents, which are otherwise administered parenterally, are disclosed. Pharmaceutical compositions containing the casein particles and uses thereof in the treatment of cancer and other conditions treatable by the encapsulated therapeutically active agent are also disclosed. Further disclosed are processes of preparing the casein particles. The disclosed casein particles are useful for orally delivering the therapeutically active encapsulate and can further be used for controllably releasing the agents in the gastrointestinal tract.Type: ApplicationFiled: February 11, 2009Publication date: February 24, 2011Inventors: Yoav D. Livney, Yehuda G. Assaraf, Alina Shapira
-
Patent number: 7888368Abstract: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of drug-resistant tumors and/or for the administration to patients who show polymorphisms in the gene coding for DNA topoisomerase I.Type: GrantFiled: December 13, 2006Date of Patent: February 15, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Claudio Pisano, Loredana Vesci
-
Publication number: 20110034542Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.Type: ApplicationFiled: November 9, 2008Publication date: February 10, 2011Inventors: Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavi
-
Publication number: 20110035232Abstract: Treatment of hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The further provided are methods for treating these subjects.Type: ApplicationFiled: June 2, 2010Publication date: February 10, 2011Applicant: SALIX PHARMACEUTICALS, LTD.Inventors: William Forbes, Kunal Merchant, Enoch Bortey, Audrey Shaw
-
Publication number: 20110033525Abstract: Several diterpene glycosides (e.g., rubusoside, rebaudioside, steviol monoside and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, and celecoxib. The use of the diterpene glycoside rubusoside increased solubility in all tested compounds. The diterpene glycosides are a naturally occurring class of water solubility-enhancing compounds that are non-toxic and that will be useful as new complexing agents or excipients in the pharmaceutical, agricultural (e.g., solubilizing pesticides), cosmetic and food industries. Aqueous solutions by using rubusoside to increase the solubility of otherwise insoluble drugs will have several new routes of administration. In addition, aqueous solutions of therapeutic compounds with rubusoside were shown to retain the known pharmacological activity of the compounds.Type: ApplicationFiled: April 13, 2009Publication date: February 10, 2011Inventor: Zhijun Liu
-
Publication number: 20110028536Abstract: Disclosed herein are methods and compositions for enhancing the sensitivity of cells to the effects of topoisomerase I inhibitors. Also disclosed are methods and compositions for inducing apoptosis and/or growth arrest which may be used for tumor suppression.Type: ApplicationFiled: August 16, 2007Publication date: February 3, 2011Inventors: Ruth A. Gjerset, Keya Bandyopadhyay
-
Publication number: 20110027277Abstract: The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase I (topo I) inhibitors in the treatment of cancers. More specifically, the present invention relates to methods, machines, computer systems, computable readable media and kits which can be used to identify and determine the effectiveness of topoisomerase I (topo I) inhibitors in the treatment of cancers, and in some embodiments, the level of sensitivity or resistance of a tumor cell to a topoisomerase I inhibitor, such as camptothecin (CPT), or CTP analogues such as topotecan and irinotecan and derivatives thereof.Type: ApplicationFiled: March 31, 2009Publication date: February 3, 2011Applicant: BOSTON MEDICAL CENTER CORPORATIONInventor: Ajit Bharti
-
Patent number: 7879868Abstract: The present invention relates to the use of imatinib of the following formula or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a cancer that expresses breast cancer resistant protein (BCRP) in a human subject in need of such a treatment.Type: GrantFiled: October 10, 2003Date of Patent: February 1, 2011Assignee: Novartis AGInventors: Peter J. Houghton, Peter Traxler
-
Publication number: 20110021451Abstract: We describe a method of generating a classification model capable of distinguishing between two biological states, the method comprising the steps of: (a) providing a training dataset, X, comprising concentrations of a plurality of lipids in a biological sample in a first state and a biological sample in a second state; (b) subjecting the training dataset X to Principal Components Analysis (PCA), in which the PCA analysis generates a transformation matrix, C, and a transformed dataset, Yl; (c) subjecting the transformed dataset Yl to Support Vector Machines (SVM) analysis, in which the SVM analysis generates a SVM model, S; (d) forming a classification model comprising (i) the transformation matrix C, and (ii) the corresponding SVM model S.Type: ApplicationFiled: January 28, 2009Publication date: January 27, 2011Applicant: NATIONAL UNIVERSITY OF SINGAPOREInventors: Markus R. Wenk, Gek Huey Chua, Aaron Zefrin Fernandis, Xueli Guan
-
Patent number: 7875290Abstract: A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isolation from the toxic or potent core. The drug in the toxic or potent core is incorporated into the dosage form via, for example, three-dimensional printing, as a solution, solubilization or suspension of solid particles in liquid, rather than by the more conventional handling and compressing of dry powder. This minimizes the likelihood of creating airborne particles of the toxic drug during manufacturing, hence controlling and minimizing the exposure of manufacturing personnel to the hazardous substance. Wet dispensing of the toxic or potent drug further provides greater bioavailability of the drug to the patient.Type: GrantFiled: October 7, 2005Date of Patent: January 25, 2011Assignee: Massachusetts Institute of TechnologyInventors: Francis C. Payumo, Jill K. Sherwood, Donald C. Monkhouse, Jaedeok Yoo, Christopher M. Gaylo, Chen-Chao Wang, Michael J. Cima
-
Publication number: 20110014204Abstract: The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents.Type: ApplicationFiled: December 7, 2007Publication date: January 20, 2011Inventors: Andrew P. Feinberg, Andre Levchenko, Dan L. Longo, Minoru S.H. Ko
-
Publication number: 20110015221Abstract: The invention relates to a pharmaceutical composition of vinflunine in the form of a stable sterile aqueous solution of a water-soluble salt of vinflunine with a pH of between 3 and 4. The invention also relates to the method of preparing said composition and to the use thereof as a parenterally-administered medicament for the treatment of cancer.Type: ApplicationFiled: July 29, 2010Publication date: January 20, 2011Applicant: PIERRE FABRE MEDICAMENTInventors: Elie LEVERD, Joël Bougaret, Marie-Dominique Ibarra
-
Publication number: 20110009353Abstract: The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell cycle progression in cancer cells. When combined with chemotherapy such cell cycle inhibition can effectively treat even aggressive cancer types that are drug-resistant and intractable to most chemotherapies.Type: ApplicationFiled: October 1, 2008Publication date: January 13, 2011Inventors: Selina Chen-Kiang, Maurizio Di Liberto, Xiangao Huang
-
Publication number: 20110008465Abstract: A pharmaceutical composition comprising a water insoluble sesquiterpene, one or more antioxidants and one or more solubilizers selected from the group consisting of an oil, PEG400, a derivative of castor oil and ethylene oxide, and polysorbate 80, and methods of use thereof.Type: ApplicationFiled: June 2, 2008Publication date: January 13, 2011Inventors: Jean Legault, Andre Pichette, Serge Lavoie
-
Publication number: 20110009325Abstract: Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate.Type: ApplicationFiled: September 20, 2010Publication date: January 13, 2011Applicant: Abbott LaboratoriesInventors: SHEKHAR VISWANATH, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
-
Patent number: 7868039Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vinca alkaloids, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vincristine. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: July 30, 2007Date of Patent: January 11, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Publication number: 20110002879Abstract: The invention provides a combination comprising a cytotoxic compound, a signalling inhibitor, an ancillary agent, or two or more further anti-cancer agents, and a compound having the formula (Ib): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4—; A is a bond, C?O, NRg(C?O) or O(C?O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from fluorine, hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy (e.g.Type: ApplicationFiled: April 1, 2010Publication date: January 6, 2011Applicant: ASTEX THERAPEUTICS LIMITEDInventors: Jayne Elizabeth CURRY, John Francis LYONS, Matthew Simon SQUIRES, Neil Thomas THOMPSON, Kyla Merriom THOMPSON, Paul Graham WYATT, Neil James GALLAGHER
-
Publication number: 20110002982Abstract: Liposomes that contain at least 10 mol % of a negatively charged lipid coupled to a non-zwitterionic moiety are stable in the blood. Liposomes containing at least 1 mol % of such lipids may be frozen safely.Type: ApplicationFiled: September 16, 2010Publication date: January 6, 2011Inventors: Paul TARDI, Murray Webb, Lawrence D. Mayer, Ludger M. Ickenstein
-
Publication number: 20110003842Abstract: Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.Type: ApplicationFiled: January 30, 2009Publication date: January 6, 2011Applicants: KEIO UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHAInventors: Yusuke Tanigawara, Mitsuhiro Watanabe, Eri Arita, Akito Nishimuta, Yasuko Yamayoshi, Takeshi Matsuzaki, Shinji Sugimoto
-
BIOACTIVE COMPOSITION FOR THE TREATMENT OF THE HIV/AIDS, METHOD FOR MANUFACTURING AND USING THE SAME
Publication number: 20110003841Abstract: The present invention is about a bioactive composition for the treatment of HIV, particularly by the removal of the most prominent HIV antigen glycoproteins. The present invention further relates to the method for making and using such composition.Type: ApplicationFiled: November 6, 2008Publication date: January 6, 2011Inventor: Mukesh Harilal Shukla -
Publication number: 20100323002Abstract: The present invention relates to the inhibition of melanogenesis with para-aminobenzoic acid (PABA) and its use in treating melanotic cancer.Type: ApplicationFiled: February 5, 2010Publication date: December 23, 2010Applicant: NEW YORK UNIVERSITYInventors: Peter C. Brooks, Danielle Morais, Dorothy Rodriguez
-
Publication number: 20100323034Abstract: Provided are an marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a calcium-binding protein S100A7, S100A8, or S100A10.Type: ApplicationFiled: January 30, 2009Publication date: December 23, 2010Applicants: Keio University, Kabushiki Kaisha Yakult HonshaInventors: Yusuke Tanigawara, Sayo Suzuki, Shinji Sugimoto
-
Publication number: 20100323033Abstract: The present invention relates to a cancer sensitizer comprising chlorogenic acid or a derivative thereof. In particular, the present invention relates to a cancer sensitizer comprising chlorogenic acid or a derivative thereof, which can make cancer cells sensitive to anticancer agents to increase the therapeutic effect of anticancer agents. In addition, the present invention relates to a composition for inhibiting the chemo-resistance of cancer cells, comprising chlorogenic acid or a derivative thereof in combination with a pharmaceutically acceptable carrier, an anticancer composition comprising an anticancer agent in addition to the composition, and a method for disrupting the chemo-resistance of cancer cells, comprising administration of the cancer sensitizer.Type: ApplicationFiled: October 1, 2008Publication date: December 23, 2010Inventors: Soo Youl Kim, Kang-Seo Park, Kyung chae Jeong
-
Publication number: 20100310684Abstract: Methods for treating and preventing mucositis, in particular mucositis following the administration of chemotherapy drugs or a combination of said drugs with radiotherapy, are disclosed herein. More specifically, disclosed herein is the administration of a therapeutically effective amount of at least one of an anthocyanoside, a proanthocyanidin, or an extract containing at least one of an anthocyanoside or a proanthocyanidin for the treatment or prevention of mucositis. The therapeutically effective amount of the anthocyanoside, proanthocyanidin or extract can be administered alone or in combination with a therapeutically effective amount of at least one of an anti-inflammatory agent, immunomodulating agent, analgesic, antimicrobial agent or antifungal agent. Also disclosed herein are pharmaceutical compositions for treating and preventing mucositis.Type: ApplicationFiled: August 16, 2010Publication date: December 9, 2010Inventors: Ezio Bombardelli, Paolo Morazzoni
-
Publication number: 20100311784Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.Type: ApplicationFiled: August 17, 2010Publication date: December 9, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITIE SPAInventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti
-
Publication number: 20100311595Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.Type: ApplicationFiled: June 14, 2010Publication date: December 9, 2010Applicant: Children's Hospital and Research Center at OaklandInventors: Robert O. RYAN, Michael N. Oda
-
Publication number: 20100311689Abstract: The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-1 or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-1 in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-1 and another therapeutic agent.Type: ApplicationFiled: October 31, 2008Publication date: December 9, 2010Applicant: ZIOPHARM Oncology, IncInventors: Barbara P. Wallner, Philip B. Komarnitsky
-
Publication number: 20100310647Abstract: The invention relates to new methods of enzymatic synthesis of polymers such as polyorganosilicones and polyesters, and new polymers made by these methods.Type: ApplicationFiled: May 5, 2010Publication date: December 9, 2010Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Rajesh Kumar, Arthur C. Watterson, Virinder Singh Parmar, Jayant Kumar, Lynne Ann Samuelson
-
Publication number: 20100311783Abstract: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.Type: ApplicationFiled: August 17, 2010Publication date: December 9, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITIE SPAInventors: Paolo Carminati, Maria Ornella Tinti, Mauro Marzi, Fabrizio Giorgi, Walter Cabri, Marco Alpegiani, Domenico Vergani, Paolo Ghetti
-
Publication number: 20100305148Abstract: The present invention is related to 10,20-di-O ester derivatives of camptothecin and pharmaceutical formulations thereof. The compounds and pharmaceutical formulations of the present invention possess increased biological life span and bioavailability and reduced toxicity, while maintaining anti-cancer activity.Type: ApplicationFiled: April 13, 2010Publication date: December 2, 2010Applicant: Abraxis BioScience, LLCInventors: Patrick Soon-Shiong, Neil P. Desai, Chunlin Tao, Cheng Zhi Yu
-
Publication number: 20100305070Abstract: The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer.Type: ApplicationFiled: April 30, 2010Publication date: December 2, 2010Applicant: The University Court of the University of DundeeInventors: Steven Albert Everett, Saraj Ulhaq
-
Publication number: 20100305149Abstract: Polyal-Drug conjugates comprising a variable rate-releasing linker are described along with methods of making such conjugates. Uses for such Polyal-Drug conjugates is also described.Type: ApplicationFiled: May 27, 2010Publication date: December 2, 2010Applicant: Mersana Therapeutics, Inc.Inventors: Aleksandr Yurkovetskiy, Mao Yin, Gui Liu, Laura C. Akullian, John J. Kane, Cheri A. Stevenson, Charles E. Hammond, Russell C. Petter, John H. Van Duzer, Timothy B. Lowinger
-
Publication number: 20100297007Abstract: The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents.Type: ApplicationFiled: October 9, 2008Publication date: November 25, 2010Applicant: THE WASHINGTON UNIVERSITYInventors: Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan
-
Publication number: 20100297075Abstract: The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.Type: ApplicationFiled: February 11, 2010Publication date: November 25, 2010Applicants: ArQule, Inc., Kyowa Hakko Kirin Co., Ltd.Inventors: Thomas C.K. Chan, Dennis S. France, Kenichi Ishii, Paolo Pucci
-
Publication number: 20100291222Abstract: The present invention is directed to multiple a-lipoic acid-containing hydrophobic compounds (mALAs) capable of acting as scavengers of free radicals, metals and reactive oxygen species (ROS). Methods of synthesizing novel antioxidant mALAs, spontaneous emulsification or nanoprecipitaion thereof to produce antioxidant nanospheres and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are also described. Another aspect of this invention is the use of these antioxidant nanospheres for the preparation of antioxidant particulate delivery system of therapeutic agents.Type: ApplicationFiled: December 30, 2008Publication date: November 18, 2010Applicant: CEDARS-SINAI MEDICAL CENTERInventors: John S. Yu, Bong Seop Lee
-
Publication number: 20100292231Abstract: Compounds of formula (I) or formula (Ia) and a method of treating a patient suffering from certain inflammatory disorders, demyelinating disorders, FLT3-mediated disorders, CSF-1R-mediated disorders, cancers and leukemias, comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or formula (Ia) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.Type: ApplicationFiled: February 2, 2010Publication date: November 18, 2010Inventors: Alfred M. Ajami, Kenneth Duncan
-
Publication number: 20100285012Abstract: The subject application provides small compounds that are able to suppress autophagy in various cells. These compounds are useful in augmenting the existing treatments of various cancers and microbial/parasitic infections. Thus, the subject application also provides methods of treating various types of cancers and microbial/parasitic infections. Also provided by the subject application are methods of suppressing the expansion of autophagosomes within cells or individuals and inhibiting the lipidation of autophagy-related protein 8 (Atg8).Type: ApplicationFiled: January 5, 2009Publication date: November 11, 2010Applicant: University of FLorida Research Foundation Inc.Inventors: William A. Dunn, JR., Debra E. Akin, Ann Progulske-Fox, David A. Ostrov
-
Publication number: 20100279957Abstract: Provided herein are methods for predicting the responsiveness of a cancer to a chemotherapeutic agent using gene expression profiles. In particular, methods for predicting the responsiveness to 5-fluorouracil, adriamycin, cytotoxan, docetaxol, etoposide, taxol, topotecan, PB kinase inhibitors and Src inhibitors are provided. Methods for developing treatment plans for individuals with cancer are also provided. Kits including gene chips and instructions for predicting responsiveness and computer readable media comprising responsivity information are also provided.Type: ApplicationFiled: October 20, 2008Publication date: November 4, 2010Inventors: Anil Potti, Joseph R. Nevins, Johnathan M. Lancaster
-
Publication number: 20100279964Abstract: The present invention relates to methods of using 3?,4?-aromatic acyloxy substituted 7,8-pyranocoumarins compounds in reversing P-glycoprotein overexpression mediated multidrug resistance in cancer cells including uses in treating cancers.Type: ApplicationFiled: July 16, 2010Publication date: November 4, 2010Inventors: Wangfun Fong, Xiaoling Shen, Guangying Chen, Guoyuan Zhu, Chikeung Wan, Kaiwing Tse
-
Publication number: 20100278932Abstract: The present invention provides micelles having SN-38 encapsulated therein.Type: ApplicationFiled: May 4, 2010Publication date: November 4, 2010Applicant: Intezyne Technologies, IncorporatedInventors: Kevin N. Sill, Habib Skaff, Adam Carie, Jonathan Rios-Doria, Richard Slama, Gregoire Cardoen
-
Publication number: 20100266540Abstract: Compositions, methods, and combination therapies for the treatment of cancers, including lymphomas, leukemias, melanomas, lung cancer, and metastatic disease, are provided. Specifically, compositions comprising ligands to Pgrmc1 are disclosed for use in treating and inhibiting tumor growth and progression and inhibition of metastases. The compositions and methods using these ligands can be used alone or in combination with other reagents and cancer treatment modalities.Type: ApplicationFiled: April 20, 2010Publication date: October 21, 2010Applicant: University of Kentucky Research FoundationInventor: Rolf Joseph CRAVEN
-
Publication number: 20100267759Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: ApplicationFiled: February 7, 2008Publication date: October 21, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
-
Publication number: 20100266570Abstract: The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I): or a pharmaceutically acceptable salt thereof with B1 and B2 selected from C?O, CHOH and CH2, as well as to their use in treating cancer and to their preparation method.Type: ApplicationFiled: December 22, 2008Publication date: October 21, 2010Applicants: Pierre Fabre Medicament, Centre National De La Recherche Scientifique, Universite Paris-Sud 11Inventors: Jean-Pierre Begue, Danièle Bonnet-Delpon, Benoît Crousse, Fabienne Grellepois, Constance Chollet, Jacques Fahy, Céline Mordant